Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Kos Pharmaceuticals, Inc (KOSP) -- Ignore unavailable to you. Want to Upgrade?

To: Jeff Briley who wrote (26)	11/12/1997 6:02:00 PM
From: Jeff Briley	Read Replies (1) \| Respond to of 118

Was just looking at First Call... noticed that KOSP actually beat estimates today!! Four analysts had a mean EPS of (-.82). The high estimate was (-.79) and the low was (-.84). KOSP beat every analyst with a loss of (-.73)!! Kos just started marketing their drug, Niaspan, in September, and Solomon Bros. downgraded them "as a result of the slow prescription trend". Come on, Solomon, give them a chance to get their foot in the pool before you drown them.... This looks like a textbook panic-sell (if there is such a thing - lol). They were only downgraded by one analyst from a buy to a hold. CNBC said that some analysts were recommending it now, and I expect to see some of these recommendations surface in the morning. The market was real weak and everybody took out their anger on poor little KOSP. Oh well... Here's to a rebound tomorrow <cheers>. Jeff